Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses
- PMID: 18606693
- DOI: 10.4049/jimmunol.181.2.1386
Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses
Abstract
Visceral leishmaniasis caused by Leishmania donovani is a life-threatening disease involving uncontrolled parasitization of liver, spleen, and bone marrow. Most available drugs are toxic. Moreover, relapse after seemingly successful therapy remains a chronic problem. In this study, we evaluated a new therapeutic approach based on combination of a low dose of amphotericin B (AmB) in association with suboptimum dose of stearylamine (SA)-bearing cationic liposomes, itself having leishmanicidal activity. We demonstrate that a single-shot therapy with this formulation caused clearance of parasites from liver and spleen below the level of detection in the selected piece of the organs of BALB/c mice. The combination was superior to free AmB and AmBisome for therapy, as well as for prevention of relapse and reinfection. Besides having better killing activity, AmB in SA liposomes, in contrast to AmBisome, maintained the immunomodulatory effect of free AmB on CD4(+) and CD8(+) T cells for IFN-gamma production, at the same time reducing the toxic effects of the drug, reflected through decline in TNF-alpha. In addition, IL-10 was down-regulated to almost negligible levels, most efficiently through therapy with SA-bearing cationic liposomes-AmB. This IL-10-deficient environment of IFN-gamma-secreting T cells probably up-regulated the enhanced IL-12 and NO production observed in splenic culture supernatants of these mice, correlating with prolonged disease suppression better than free AmB and AmBisome. The ability of the formulation to elicit protective immunity was reconfirmed in a prophylactic model. Our results emphasize the requirement of effective immune stimulation, additionally, by antileishmanials for persistent disease protection, demonstrated by this liposomal AmB formulation.
Similar articles
-
Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.BMC Infect Dis. 2015 Apr 17;15:188. doi: 10.1186/s12879-015-0928-6. BMC Infect Dis. 2015. PMID: 25884796 Free PMC article.
-
Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.PLoS One. 2011 Mar 10;6(3):e17376. doi: 10.1371/journal.pone.0017376. PLoS One. 2011. PMID: 21423750 Free PMC article.
-
Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.Antimicrob Agents Chemother. 1996 May;40(5):1214-8. doi: 10.1128/AAC.40.5.1214. Antimicrob Agents Chemother. 1996. PMID: 8723469 Free PMC article.
-
Amphotericin B: A drug of choice for Visceral Leishmaniasis.Acta Trop. 2022 Nov;235:106661. doi: 10.1016/j.actatropica.2022.106661. Epub 2022 Aug 20. Acta Trop. 2022. PMID: 35998680 Review.
-
Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.Drugs. 1998 Sep;56(3):365-83. doi: 10.2165/00003495-199856030-00008. Drugs. 1998. PMID: 9777313 Review.
Cited by
-
Arsenic exposure to mouse visceral leishmaniasis model through their drinking water linked to the disease exacerbation via modulation in host protective immunity: a preclinical study.Sci Rep. 2023 Dec 5;13(1):21461. doi: 10.1038/s41598-023-48642-z. Sci Rep. 2023. PMID: 38052913 Free PMC article.
-
Amphotericin B Nano-Assemblies Circumvent Intrinsic Toxicity and Ensure Superior Protection in Experimental Visceral Leishmaniasis with Feeble Toxic Manifestation.Vaccines (Basel). 2023 Jan 1;11(1):100. doi: 10.3390/vaccines11010100. Vaccines (Basel). 2023. PMID: 36679946 Free PMC article.
-
Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.Pharmaceutics. 2022 Dec 28;15(1):99. doi: 10.3390/pharmaceutics15010099. Pharmaceutics. 2022. PMID: 36678729 Free PMC article. Review.
-
Preparation, characterization, and evaluation of eosin B-loaded nano-liposomes for growth inhibition of Plasmodium falciparum.Parasitol Res. 2022 Jan;121(1):383-393. doi: 10.1007/s00436-021-07395-2. Epub 2022 Jan 6. Parasitol Res. 2022. PMID: 34993631
-
Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.J Nanobiotechnology. 2021 Apr 15;19(1):106. doi: 10.1186/s12951-021-00853-0. J Nanobiotechnology. 2021. PMID: 33858436 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials